Phase 2
Completed N=117
A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.
Source: ClinicalTrials.gov NCT00595101 ↗Enrolled (actual)
117
Serious AEs
0.0%
Results posted
Aug 2020
Primary outcomePrimary: Change From Baseline Mean Diurnal Intraocular Pressure (IOP) in the Study Eye on Day 28 — -5.12; -5.94; -5.02; -5.25 mmHg (milimeters of mercury)
Summary
To investigate dose response, safety and efficacy of PF-03187207 in patients with primary open-angle glaucoma or ocular hypertension
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline Mean Diurnal Intraocular Pressure (IOP) in the Study Eye on Day 28 |
-5.12; -5.94; -5.02; -5.25 | — |
| SECONDARY Change From Baseline in Mean Intraocular Pressure (IOP) at Specific Time Points on Day 14 and Day 28 |
-5.20; -5.87; -4.35; -5.53; -5.63; -6.11 | — |
| SECONDARY Target IOP |
9; 11; 13; 9; 4; 2 | — |
Eligibility Criteria
Inclusion Criteria
- Man or woman at least 20 years of age
- Diagnosis of primary open-angle glaucoma or ocular hypertension in one or both eyes.
Exclusion Criteria
- Closed/barely open anterior chamber angle or a history of acute angle closure in either eye
- Contraindications to latanoprost and nitric oxide treatment
- Known latanoprost non-responders
Data sourced from ClinicalTrials.gov (NCT00595101). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.